NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

皮膚癌診斷及治療藥市場調查報告:各疾病類型,診斷,不同治療-2025年為止的預測-COVID-19累積的影響

Skin Cancer Diagnostics & Therapeutics Market Research Report by Disease Type, by Diagnosis, by Treatment, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 1006259
出版日期 內容資訊 英文 185 Pages
商品交期: 最快1-2個工作天內
價格
皮膚癌診斷及治療藥市場調查報告:各疾病類型,診斷,不同治療-2025年為止的預測-COVID-19累積的影響 Skin Cancer Diagnostics & Therapeutics Market Research Report by Disease Type, by Diagnosis, by Treatment, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 185 Pages
簡介

全球皮膚癌診斷及治療藥的市場規模預測將從2020年的56億5,687萬美元,擴大到2025年末的88億4,705萬美元。

COVID-19是前所未有的全球性公共衛生突發事件,已影響到每個行業。這種長期影響預計將在預測期內影響行業增長。我們正在進行的研究正在擴大我們的研究範圍,以確保我們窮究潛在的COVID-19問題和未來路徑。該報告考慮了消費者行為和需求的變化,購買方式,供應鏈的重新改道,當前市場趨勢以及政府的重要介入等因素,提供有關COVID-19的洞察,分析,與預測。

本報告提供皮膚癌診斷及治療藥市場相關調查,提供市場概要,以及各疾病類型,診斷,不同治療,各地區的趨勢,COVID-19累積的影響,及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

  • 調查的目的
  • 市場區隔和範圍
  • 調查涵蓋年份
  • 貨幣和價格
  • 語言
  • 限制事項
  • 利害關係者

第2章 調查手法

  • 調查流程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:調查設備
    • 收集:資料來源
    • 分析:資料的解釋
    • 制定:資料檢驗
    • 公開:調查報告
    • 重複:報告的更新
  • 調查的實行
    • 開始:調查流程
    • 計劃:調查計劃作成
    • 實行:調查實施
    • 檢驗:發現與分析
    • 出版物:調查報告
  • 調查成果

第3章 摘要整理

  • 簡介
  • 市場預測
  • 各疾病類型預測
  • 各診斷預測
  • 不同治療預測
  • 各地區預測
  • 其他競爭公司預測

第4章 市場概要

  • 簡介
  • COVID-19累積的影響

第5章 市場洞察

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特五力分析
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 客戶談判力
    • 供給企業談判力
    • 產業的競爭

第6章 皮膚癌診斷及治療藥市場,各疾病類型

  • 黑色素瘤
  • 非黑色素瘤

第7章 皮膚癌診斷及治療藥市場,各診斷

  • 血液檢驗
  • 皮膚鏡檢查
  • 影像檢查
  • 淋巴節切片檢查
  • 皮膚切片檢查

第8章 皮膚癌診斷及治療藥市場,不同治療

  • 化療
  • 非侵入性療法
  • 手術

第9章 南北美洲的皮膚癌診斷及治療藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區的皮膚癌診斷及治療藥市場

  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第11章 歐洲,中東·非洲的皮膚癌診斷及治療藥市場

  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國
  • 英國

第12章 競爭情形

  • FPNV定位矩陣
    • 象限
    • 事業策略
    • 產品的滿意度
  • 市場排行榜分析
  • 市場佔有率分析
  • 其他競爭公司的SWOT分析
  • 競爭模式
    • 合併和收購
    • 契約,合作,及夥伴關係
    • 新產品的銷售與強化
    • 投資與資金籌措
    • 獎,獎勵,擴大

第13章 企業的實用性簡介

  • AB Science
  • Abbott Laboratories
  • Amgen, Inc
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Castle Biosciences, Inc
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • NeraCare GmbH
  • Novartis AG
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.

第14章 附錄

  • 討論指南
  • 許可證和價格
  • 聯絡處詳細內容

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-4342CA3266EE

The Global Skin Cancer Diagnostics & Therapeutics Market size was estimated at USD 5,656.87 Million in 2020 and expected to reach USD 6,214.44 Million in 2021, at a Compound Annual Growth Rate (CAGR) 10.19% to reach USD 10,128.49 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Skin Cancer Diagnostics & Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease Type, the Skin Cancer Diagnostics & Therapeutics Market was studied across Melanoma and Non-melanoma.

Based on Diagnosis, the Skin Cancer Diagnostics & Therapeutics Market was studied across Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy.

Based on Treatment, the Skin Cancer Diagnostics & Therapeutics Market was studied across Chemotherapy, Non-invasive Therapy, and Surgery.

Based on Geography, the Skin Cancer Diagnostics & Therapeutics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Skin Cancer Diagnostics & Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Skin Cancer Diagnostics & Therapeutics Market, including AB Science, Abbott Laboratories, Amgen, Inc, Amgen, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Castle Biosciences, Inc, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Merck & Co., Inc., NeraCare GmbH, Novartis AG, Pfizer Inc., Qiagen NV, Sanofi SA, and Sun Pharmaceutical Industries Ltd..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Skin Cancer Diagnostics & Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 6. What is the market share of the leading vendors in the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Skin Cancer Diagnostics & Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Disease Type Outlook
  • 3.4. Diagnosis Outlook
  • 3.5. Treatment Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of skin cancer globally
      • 5.1.1.2. Rising awareness on skin cancer among people
      • 5.1.1.3. Proliferation in research and development pipelines for skin cancer drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging advanced healthcare infrastructure globally
      • 5.1.3.2. Introduction of new diagnostics and therapeutic products
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulatory mandates for diagnostics and therapeutics
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Skin Cancer Diagnostics & Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Melanoma
  • 6.3. Non-melanoma

7. Skin Cancer Diagnostics & Therapeutics Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood Tests
  • 7.3. Dermatoscopy
  • 7.4. Imaging Tests
  • 7.5. Lymph Node Biopsy
  • 7.6. Skin Biopsy

8. Skin Cancer Diagnostics & Therapeutics Market, by Treatment

  • 8.1. Introduction
  • 8.2. Chemotherapy
  • 8.3. Non-invasive Therapy
  • 8.4. Surgery

9. Americas Skin Cancer Diagnostics & Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Skin Cancer Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Skin Cancer Diagnostics & Therapeutics Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. AB Science
  • 13.2. Abbott Laboratories
  • 13.3. Amgen, Inc
  • 13.4. Amgen, Inc.
  • 13.5. AstraZeneca PLC
  • 13.6. Bristol-Myers Squibb Company
  • 13.7. Castle Biosciences, Inc
  • 13.8. Daiichi Sankyo Company, Limited
  • 13.9. F. Hoffmann-La Roche Ltd
  • 13.10. GlaxoSmithKline PLC
  • 13.11. Merck & Co., Inc.
  • 13.12. NeraCare GmbH
  • 13.13. Novartis AG
  • 13.14. Pfizer Inc.
  • 13.15. Qiagen NV
  • 13.16. Sanofi SA
  • 13.17. Sun Pharmaceutical Industries Ltd.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2026
  • FIGURE 11. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2020 VS 2026 (%)
  • FIGURE 16. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2026
  • FIGURE 18. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2026 (USD MILLION)
  • FIGURE 19. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, 2018-2026 (USD MILLION)
  • FIGURE 21. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2020 VS 2026 (%)
  • FIGURE 29. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2026
  • FIGURE 31. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2026 (USD MILLION)
  • FIGURE 36. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 38. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 40. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. CALIFORNIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. FLORIDA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. ILLINOIS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. NEW YORK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. OHIO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. PENNSYLVANIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. TEXAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 53. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 54. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 55. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 56. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 64. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 65. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 66. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 76. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 77. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 78. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 79. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 80. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. CALIFORNIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. CALIFORNIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. CALIFORNIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. FLORIDA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. FLORIDA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. FLORIDA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. ILLINOIS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. ILLINOIS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. ILLINOIS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. NEW YORK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. NEW YORK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. NEW YORK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. OHIO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. OHIO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. OHIO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. PENNSYLVANIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. PENNSYLVANIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. PENNSYLVANIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. TEXAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. TEXAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. TEXAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SCORES
  • TABLE 123. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 124. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 125. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: RANKING
  • TABLE 126. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 127. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 128. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 129. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 130. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 131. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 132. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 133. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: LICENSE & PRICING
  • TABLE 134. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: CONTACT DETAILS